Ruthenium-carbohydrate conjugates as cytostatic drugs with an enhanced selectivity to cancer cells

01.01.2017 - 31.12.2019
Grantová agentura: 
Typ grantu: 
Standardní projekt
Registrační číslo: 
Interní řešitel/spoluřešitel: 
Karban Jindřich
Interní řešitel: 
je pouze spoluřešitelem
Externí řešitel/spoluřešitel: 
Jiří Pinkas, J. Heyrovsky Institute of Physical Chemistry CAS and Roman Hrstka, Masaryk Memorial Cancer Institute

Cancer cells frequently display an order higher d-glucose uptake in comparison to normal ones (Warburg effect). Accordingly, cancer cells express higher levels of glucose and other monosaccharide transporters in the cytoplasmic membrane. The project goal is to develop organometallic cytotoxic species profiting from Warburg effect and displaying enhanced efficacy for cancer cell lines. The series of ruthenium-carbohydrate conjugates will be prepared and the effect of the carbohydrate on cytotoxicity, transport, and selectivity will be investigated.